June 29, 2022
At PSYCH Symposium: London 2022, Kernel’s Chief Technology Officer, Ryan Field, delivered a presentation on the use of the company’s
June 22, 2022
Eating disorders, such as anorexia nervosa, bulimia nervosa and binge eating, afflict approximately 20 million people in Europe. In the
June 15, 2022
Psych Capital Plc, the psychedelic healthcare incubation and investment company which operates PSYCH, has began trading on the Aquis Stock
June 7, 2022
Telehealth harnesses telecommunications to enhance the accessibility of psychedelic healthcare, delivering medical services to patients digitally. Services that can be
May 31, 2022
In a milestone for psychedelic healthcare, Oregon has published the first regulations for its psilocybin framework – governing product, testing
May 24, 2022
Ceruvia Lifesciences focuses on the discovery, development, and delivery of psychedelic medicines to address hard-to-treat disorders such as headache disorders,
May 18, 2022
On Wednesday, 11 May, thought leaders from across psychedelic healthcare converged at the National Gallery for the inaugural, and sold
May 10, 2022
The following article was originally published by Psychedelic Alpha. As the psychedelic sector continues to mature, stakeholders from an ever-growing
May 10, 2022
Biomind Labs At PSYCH Symposium Biomind Labs announced it was relocating from Toronto to Cambridge, recognising the opportunities in Europe’s
May 4, 2022
Negev Capital With US$30 million under its management, Negev Capital is a fund focused on psychedelic drug development, with investments
April 27, 2022
At the start of 2022, the FDA cleared MindMed’s Investigational New Drug (IND) application for MM-120, paving the way for
April 19, 2022
On 19 April 1943, Albert Hofmann intentionally consumed LSD, marking the first recorded experience with the psychedelic medicine. When Hofmann
